Learn More
PURPOSE Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferative activity. A randomized, double-blind, placebo-controlled phase IIB trial assessed sorafenib with capecitabine for(More)
636 Background: Combination therapy of vinorelbine (N) and trastuzumab (H) has recently been shown to be an active and safe regimen for HER2 positive MBC patients (Burstein JCO 01, 19;2722-2730).(More)
  • 1